Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | — | 1 |
Drug common name | Cenicriviroc |
INN | cenicriviroc |
Description | Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug and an anti-inflammatory agent. It is a diether, a member of imidazoles, a sulfoxide, an aromatic ether, a secondary carboxamide and a benzazocine. |
Classification | Small molecule |
Drug class | antivirals; antivirals, chemokine receptor (CCR) antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1 |
PDB | — |
CAS-ID | 497223-25-3 |
RxCUI | — |
ChEMBL ID | CHEMBL2110727 |
ChEBI ID | — |
PubChem CID | 11285792 |
DrugBank | DB11758 |
UNII ID | 15C116UA4Y (ChemIDplus, GSRS) |